We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The US Centers for Disease Control and Prevention (CDC) has applied for a US patent on the coronavirus that causes severe acute respiratory syndrome (SARS).

CDC director Julie Gerberding says the move is an attempt to head off companies that might monopolise future diagnostics and treatments for SARS.

But the situation may develop into a full-scale intellectual-property battle between the CDC and other competitors for patent rights, which include the University of Hong Kong and the British Columbia Cancer Agency in Canada.

Link to Nature news in brief

Reference: Nature 423, 214 (2003)

Related SciDev.Net article:

SciDev.Net's resources on SARS and Developing Countries